Cargando…

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

There has been a worldwide increase in infections caused by drug-resistant Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE). Meropenem-vaborbactam, a carbapenem antibiotic and novel boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petty, Lindsay A, Henig, Oryan, Patel, Twisha S, Pogue, Jason M, Kaye, Keith S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140735/ https://www.ncbi.nlm.nih.gov/pubmed/30254477 http://dx.doi.org/10.2147/IDR.S150447

Ejemplares similares

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
por: Albin, Owen, et al.
Publicado: (2018)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
por: Wunderink, Richard G., et al.
Publicado: (2018)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

2222. Impact of Empiric Aminoglycoside Usage on Outcomes in Bacterial Pneumonia
por: Albin, Owen, et al.
Publicado: (2019)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis
por: Bassetti, Matteo, et al.
Publicado: (2019)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
por: Bhowmick, Tanaya, et al.
Publicado: (2020)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
por: Henig, Oryan, et al.
Publicado: (2019)

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China
por: Huang, Na, et al.
Publicado: (2021)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

2131. Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2019)

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
por: Castanheira, Mariana, et al.
Publicado: (2023)

Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review
por: Lashinsky, Jennifer N., et al.
Publicado: (2017)

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures
por: Squires, Kevin M, et al.
Publicado: (2023)

1676. PK, Safety and Tolerability of VABOMERE(®) (meropenem-vaborbactam) in Infants, Children and Adolescents
por: Bokesch, Paula M, et al.
Publicado: (2023)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

2443. Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing Enterobacteriaceae: Aztreonam Plus Ceftazidime–Avibactam vs. Aztreonam Plus Meropenem–Vaborbactam
por: Biagi, Mark, et al.
Publicado: (2018)

610. Meropenem-vaborbactam (MV) In Vitro Activity Against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Isolates with Outer Membrane Porin Gene Mutations
por: Yasmin, Mohamad, et al.
Publicado: (2019)

Bacterial Pneumonia in Older Adults
por: Henig, Oryan, et al.
Publicado: (2017)

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
por: Trang, M., et al.
Publicado: (2021)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date
por: Herald, Fischer, et al.
Publicado: (2023)

A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: Henig, Oryan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hig3rmo9qill12sufl0kr3t3hr